There are ongoing human clinical trials of antisense oligonucleotide therapy and hydroxychloroquine (AURORA [Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene; NCT04123626]; and RHO [Oral Hydroxychloroquine {HCQ} for Retinitis Pigmentosa Caused by P23H-Rhodopsin; NCT04120883]), respectively, for patients harboring the RHO variant P23H. The gene discussed is RHO; the disease is retinitis pigmentosa.